DNLI - Healthcare And Biotech Outlook For The Rest Of 2020

• As the pandemic resurges, early vaccine trials are reaching the home stretch.
• Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments.
• Healthcare overall has been burdened by the uncertainty on the Affordable Care Act, but biotechs and medical devices/services shine.
• Biotechs are well-positioned to move higher after undergoing a few months of consolidation.
• Both Biotechnology and Healthcare present attractive opportunities for material gains during the final quarter, in the absence of a contested election.

For further details see: